

352.309.6605 matthew.bellefleur@mcneillbaur.com McNeill Baur PLLC 10752 Deerwood Park Boulevard South Suite 100 Jacksonville, FL 32256

## **Admissions**US Patent and Trademark Office

## Arizona State University PhD, Microbiology, 2018

University of Michigan BS, Microbiology, 2012

# Matthew P.A. Bellefleur, PhD Patent Agent

Utilizing research and prosecution experience to provide value to clients in a wide range of life science-based technologies

Matthew P.A. Bellefleur, PhD, focuses his practice on patent drafting and prosecution in the life sciences. He has experience covering a wide range of technologies, including microbiology; molecular biology; antibodies; engineered or recombinant DNA, RNA, and proteins; genetically modified cells; and nucleotide detection technologies.

Matthew earned his doctoral degree from Arizona State University where his research focused on genetically modified bacteria. Specifically, Matthew investigated the role of bacterial efflux proteins in moving industrially relevant chemicals, including free fatty acids, out of a bacterial cell. Before attending graduate school, Matthew was a research assistant in the Department of Anesthesiology at the University of Michigan Medical School, where he investigated states of sleep and wakefulness. As part of his work, he studied the role of regulator of G protein signaling (RGS) proteins in sleep regulation.

Prior to joining McNeill Baur PLLC, Matthew worked as a technical specialist and patent agent at Saliwanchik, Lloyd & Eisenschenk, where he developed his patent drafting and prosecution skills.

#### **Select Publications**

"Characterizing Active Transportation Mechanisms for Free Fatty Acids and Antibiotics in Synechocystis sp. PCC 6803," BMC Biotechnology 19(5), 2019 (coauthor).

"Serotype distribution, antimicrobial susceptibility, antimicrobial resistance genes and virulence genes of Salmonella isolated from a pig slaughterhouse in Yangzhou, China," AMB Express 9(210), 1-12, 2019 (coauthor).

"Impact of the Variations in Potential Glycosylation Sites of the Hemagglutinin of H9N2 Influenza Virus," Virus Genes 55, 182-190, 2019, (coauthor).

"Live-Attenuated Salmonella Enterica Serotype Choleraesuis Vaccine with Regulated Delayed Fur Mutation Confer Protection against Streptococcus Suis in Mice, " BMC Veterinary Research 16(129), 1-16, 2020 (coauthor).

### **Select Speaking Engagements**

Lunch & Learn: UF Innovate | Sid Martin Biotech, "Patentability & Patent Strategy – What to Consider for your IP Portfolio," November 15, 2022.

